CTNI-70. LONG-TERM SURVIVAL IN GLIOBLASTOMA PATIENTS AFTER TUMOR TREATING FIELDS (TTFIELDS) THERAPY

PURPOSE: Glioblastoma multiforme (GBM) is the most common and malignant primary intracranial tumor and traditionally has a median survival of only 10 to 14 months, with only 3 to 5% of patients surviving more than three years. Recurrence (RGBM) is nearly universal, and further decreases the median s...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Neuro Oncol
Egile Nagusiak: Rulseh, Aaron, Derner, Adam, Sroubek, Jan, Klener, Jan, Vymazal, Josef
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2020
Gaiak:
Clinical Trials: Non-Immunologic
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651202/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.236
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak